Abstract
Ki-67, a marker of cellular proliferation, is increasingly being used in pre-surgical window studies in endometrial cancer as a primary outcome measure. Unlike in breast cancer, however, there are no guidelines standardizing its measurement and its clinical relevance as a response biomarker is undetermined. It is, therefore, imperative that Ki-67 scoring protocols are optimized and its association with patient survival rigorously evaluated, in order to be able to clinically interpret the results of these studies. Using the International Ki-67 in Breast Cancer Working Group guidelines as a basis, whole slide, hot spot and invasive edge scoring protocols were evaluated using endometrial biopsies and hysterectomy specimens from 179 women. Whole sections and tissue microarrays, manual and semi-automated scoring using Definiens Developer software were additionally compared. Ki-67 scores were related to clinicopathological variables and cancer-specific survival in uni-and multivariate analysis. Against criteria of time efficiency, intra-and inter-observer variability and consistency, semi-automated hot spot scoring was the preferred method. Ki-67 scores positively correlated with grade, stage and depth of myometrial invasion (P-values all <0.03). By univariate analysis, higher Ki-67 scores were associated with a significant reduction in cancer-specific survival (P
Original language | English |
---|---|
Pages (from-to) | 459-468 |
Number of pages | 10 |
Journal | Modern Pathology |
Volume | 30 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar-2017 |
Keywords
- BREAST-CANCER
- ENDOCRINE THERAPY
- PROLIFERATION
- CARCINOMA
- METFORMIN
- EXPRESSION
- KI67
- MARKER
- TRIAL